RayKnowChina Research Map
Shortlist

BeijingCapital Medical University

Beijing Children's Hospital

首都医科大学附属北京儿童医院

Listed for 29 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Beijing Children's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatoblastoma肝母细胞瘤4 papers led
  2. Retinoblastoma视网膜母细胞瘤6 papers led
  3. Osteosarcoma骨肉瘤5 papers led
  4. Neuroblastoma神经母细胞瘤33 papers led1 open trial led
  5. Ewing sarcoma尤文肉瘤4 papers led
  6. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病4 papers led
  7. Aplastic anaemia再生障碍性贫血9 papers led
  8. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症31 papers led1 open trial led
  9. Beta thalassaemiaβ 地中海贫血1 paper led
  10. Haemophilia A血友病 A32 papers led
  11. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征2 papers led
  12. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  13. Fanconi anaemia范可尼贫血1 paper led
  14. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
  15. Moyamoya disease烟雾病2 papers led
  16. Biliary atresia胆道闭锁15 papers led
  17. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎4 papers led
  18. Takayasu arteritis大动脉炎3 papers led
  19. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  20. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  21. Fabry disease法布雷病0 papers led
  22. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  23. Behçet disease白塞病1 paper led
  24. Alport syndromeAlport 综合征1 paper led
  25. IgA nephropathyIgA 肾病7 papers led
  26. Gaucher disease戈谢病0 papers led
  27. Hirschsprung disease先天性巨结肠13 papers led
  28. Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
  29. Majeed syndromeMajeed 综合征0 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Chordoma, Gastrointestinal stromal tumour, Multiple myeloma, IgG4-related disease, Myasthenia gravis, Wilson disease, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Pompe disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatoblastoma

肝母细胞瘤

Led 4 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 2.6%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 1120242025: 002025

9 hospitals in Beijing for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 6 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 2.0%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 3320232024: 0020242025: 002025

10 hospitals in Beijing for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgeryMedical oncologyPediatricsOphthalmology / neuro-ophthalmology
Papers it led6
  1. Incidental detection of retinoblastoma from accidental trauma in children.2023BMC ophthalmology
  2. Clinical characteristics, treatment and prognosis of infants with retinoblastoma: a multicenter, 10-year retrospective analysis.2023BMC pediatrics
  3. The survival analysis and feasibility study of Pars Plana Vitrectomy (PPV) in the treatment of retinoblastoma.2023Journal of cancer research and clinical oncology
  4. Spectrum and tissue distribution of RB1 pathogenic alleles in mosaic retinoblastoma patients.2022Ophthalmic genetics
  5. Clinical Features and Survival of Chinese Children With Trilateral Retinoblastoma During 2006-2019: A Retrospective Multicenter Study.2021American journal of ophthalmology
  6. RB1 germline mutation spectrum and clinical features in patients with unilateral retinoblastomas.2021Ophthalmic genetics
Earlier papers (2016–2020)6
  1. Retinoblastoma in a child with tuberous sclerosis complex.2020Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  2. Economic burden for retinoblastoma patients in China.2020Journal of medical economics
  3. Impact of Systemic Chemotherapy and Delayed Enucleation on Survival of Children with Advanced Intraocular Retinoblastoma.2020Ophthalmology. Retina
  4. Reply.2018Ophthalmology
  5. Pars Plana Vitrectomy and Endoresection of Refractory Intraocular Retinoblastoma.2018Ophthalmology
  6. [The key points in intravenous chemotherapy and intra-arterial chemotherapy on retinoblastoma treatment].2017[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of RetinoblastomaStatus unknownNCT04990271Study sitePhase 2Start 2021-07

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 5 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 2220242025: 002025

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyENT / head & neck surgeryPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 33 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 2.9%.

Papers led
33
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 4420222023: 9920232024: 4420242025: 882025

24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06818916

    Age Not stated to 18 years (registered criteria)

    Led by Beijing Children's HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPediatricsPathology / laboratory medicineNeurology
Papers it led33
  1. Identification of coilin in bone marrow as a potential neuroblastoma tumor progression marker transcriptionally regulated by MYCN.2026Cancer biology & therapy
  2. A Primary Report 166 Cases of Abdominal or Pelvic Neuroblastoma Surgery Utilizing the International Neuroblastoma Surgical Report Form (INSRF).2025Annals of surgery
  3. The changes of immune function after neuroblastoma chemotherapy and the prediction of potential immune targets.2025BMC medical genomics
  4. Causal links between congenital malformations, birth weight, and neuroblastoma: insights from Mendelian randomization.2025BMC pediatrics
  5. Genetic insights into neuroblastoma: the role of immune cell features.2025Cytokine
  6. Development of a Predictive Model Based on Ultrasonographic Characteristics to Distinguish Neonatal Adrenal Cystic Neuroblastoma From Hematoma.2025Journal of clinical ultrasound : JCU
  7. The causal relationship between immune cells and neuroblastoma: a Mendelian randomization study.2025Molecular neurobiology
  8. Aberrant serum lipid levels predict clinical outcomes in patients with neuroblastoma.2025Pediatric hematology and oncology
  9. Risk factors and predictive thresholds for postoperative pleural effusion in children with neuroblastoma: a retrospective cohort study.2025World journal of surgical oncology
  10. Risk factors, impact and treatment of postoperative lymphatic leakage in children with abdominal neuroblastoma operated on by laparotomy.2024BMC surgery
  11. Therapeutic SHPRH-146aa encoded by circ-SHPRH dynamically upregulates P21 to inhibit CDKs in neuroblastoma.2024Cancer letters
  12. Renal preservation in high-risk retroperitoneal neuroblastoma: Impact on survival and local progression.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  13. Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood.2024Neurology(R) neuroimmunology & neuroinflammation
  14. Nectin2 influences cell apoptosis by regulating ANXA2 expression in neuroblastoma.2023Acta biochimica et biophysica Sinica
  15. Clinical and molecular epidemiologic features of enterovirus D68 infection in children with acute lower respiratory tract infection in China.2023Archives of virology
  16. TAF1D promotes proliferation by transcriptionally activating G2/M phase-related genes in MYCN-amplified neuroblastoma.2023Cancer science
  17. Elevated exosome-transferrable lncRNA EPB41L4A-AS1 in CD56bright NK cells is responsible for the impaired NK function in neuroblastoma patients by suppressing cell glycolysis.2023Clinical immunology (Orlando, Fla.)
  18. Synchronous Hepatoblastoma and Neuroblastoma in Two Chinese Infants.2023Fetal and pediatric pathology
  19. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma.2023Journal of molecular medicine (Berlin, Germany)
  20. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma.2023Pediatric blood & cancer
  21. Translational practice of fluorescence in situ hybridisation to identify neuroblastic tumours with TERT rearrangements.2023The journal of pathology. Clinical research
  22. Safety and feasibility of laparoscopic resection of abdominal neuroblastoma without image-defined risk factors: a single-center experience.2023World journal of surgical oncology
  23. MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.2022Cancer medicine
  24. The transcription factor TOX is involved in the regulation of T-cell exhaustion in neuroblastoma.2022Immunology letters
  25. Clinical and surgical outcome differences on the basis of pathology category in cervical neuroblastic tumors.2022Journal of pediatric surgery
  26. The expression of PHOX2B in bone marrow and peripheral blood predicts adverse clinical outcome in non-high-risk neuroblastoma.2022Pediatric hematology and oncology
  27. Mesenchymal stem cells accelerated growth and metastasis of neuroblastoma and preferentially homed towards both primary and metastatic loci in orthotopic neuroblastoma model.2021BMC cancer
  28. Biological features and clinical outcome in infant neuroblastoma: a multicenter experience in Beijing.2021European journal of pediatrics
  29. Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.2021Italian journal of pediatrics
  30. The development and initial evaluation of referral flowchart for suspected neuroblastoma for pediatricians in nononcology clinics in China.2021Pediatric blood & cancer
  31. Coexistence of orbital rhabdomyosarcoma and adrenal neuroblastic tumor in a child.2021Pediatrics international : official journal of the Japan Pediatric Society
  32. Primary renal ganglioneuroblastoma mimicking Wilms' tumor in a 3-year-old girl.2021Pediatrics international : official journal of the Japan Pediatric Society
  33. MYC-associated protein X binding with the variant rs72780850 in RNA helicase DEAD box 1 for susceptibility to neuroblastoma.2021Science China. Life sciences
Chinese-language papers (not in the count)6
  1. [Role and mechanism of cysteine and glycine-rich protein 2 in the malignant progression of neuroblastoma].2024Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  2. [Clinical and prognostic analysis of opsoclonus-myoclonus-ataxia syndrome in children].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  3. [Research progresses of tumor associated macrophages in neuroblastoma].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
  4. [Clinical characteristics and prognostic analyses of cervical neuroblastoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  5. [Research progress on the relationship between epigenetics and neuroblastoma in children].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
  6. [Two cases of neuroblastoma in the triplets].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
Earlier papers (2016–2020)22
  1. Downregulated NORAD in neuroblastoma promotes cell proliferation via chromosomal instability and predicts poor prognosis.2020Acta biochimica Polonica
  2. Clinical characteristics and risk factors of 47 cases with ruptured neuroblastoma in children.2020BMC cancer
  3. Increased plasma concentration of cell-free DNA precedes disease recurrence in children with high-risk neuroblastoma.2020BMC cancer
  4. The increased IL-17-producing γδT cells promote tumor cell proliferation and migration in neuroblastoma.2020Clinical immunology (Orlando, Fla.)
  5. Analysis of treatment cost for neuroblastoma to the family: a single-center cross-sectional study in China.2020Journal of medical economics
  6. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma.2020Journal of neuroinflammation
  7. Apatinib plus retinoic acid as maintenance for children with relapsed stage 4 high-risk neuroblastoma: Two case reports.2020Medicine
  8. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma.2020Molecular oncology
  9. Comprehensive Characterization of Circular RNAs in Neuroblastoma Cell Lines.2020Technology in cancer research & treatment
  10. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].2020Zhonghua er ke za zhi = Chinese journal of pediatrics
  11. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.2019Cancer communications (London, England)
  12. Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma.2019Cancer medicine
  13. Diminished cytolytic activity of γδ T cells with reduced DNAM-1 expression in neuroblastoma patients.2019Clinical immunology (Orlando, Fla.)
  14. lncRNA SNHG16 is associated with proliferation and poor prognosis of pediatric neuroblastoma.2019International journal of oncology
  15. IGF-1 alleviates serum IgG-induced neuronal cytolysis through PI3K signaling in children with opsoclonus-myoclonus syndrome and neuroblastoma.2019Pediatric research
  16. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].2019Zhonghua er ke za zhi = Chinese journal of pediatrics
  17. Serum Interleukin-6 Level and the rs1800795 Polymorphism in its Gene Associated with Neuroblastoma Risk in Chinese Children.2018Chinese medical journal
  18. Discrimination of histopathologic types of childhood peripheral neuroblastic tumors based on clinical and biological factors.2018Scientific reports
  19. γδTFH cells promote B cell maturation and antibody production in neuroblastoma.2017BMC immunology
  20. Role of diffusion-weighted imaging in distinguishing thoracoabdominal neuroblastic tumours of various histological types and differentiation grades.2017Journal of medical imaging and radiation oncology
  21. Maternal smoking during pregnancy and risk of childhood neuroblastoma: Systematic review and meta-analysis.2016Journal of cancer research and therapeutics
  22. Single nucleotide polymorphism rs11669203 in TGFBR3L is associated with the risk of neuroblastoma in a Chinese population.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
All its trials on ClinicalTrials.gov, any status1
  1. Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With NeuroblastomaRecruitingNCT06818916Lead sponsorN/AStart 2024-06

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 4 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 2.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 002025

17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06564272

    Age 12 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyENT / head & neck surgeryPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 4 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 112025

10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05334823

    Age 3 years to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChildrenPhiladelphia chromosome & geneticsSide effects (CRS, neurotoxicity)

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 9 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 2.2%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 1120232024: 2220242025: 222025

6 hospitals in Beijing for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesChildrenImmunosuppressive treatmentStem cell transplant
Departments in papersMedical oncology
Papers it led9
  1. A case of ADH5/ALDH2 deficiency combined with 3q29 microduplication syndrome.2025BMC pediatricsFree full text
  2. Eltrombopag combined with immunosuppressive therapy for pediatric severe aplastic anemia.2025Pediatric research
  3. Clinical characteristics of hepatitis-associated aplastic anemia in children.2024Annals of hematology
  4. Haploidentical hematopoietic stem cell transplantation as a first-line treatment for paediatric severe aplastic anemia: a single-center research.2024International journal of medical sciencesFree full text
  5. Elevated TCR-αβ+ double-negative T cells in pediatric patients with acquired aplastic anemia.2023Clinica chimica acta; international journal of clinical chemistry
  6. Effect of Wuzhi capsules on cyclosporine A concentration in children with aplastic anemia immunotherapy: a single-center observational study.2022Expert review of clinical pharmacology
  7. Immune Reconstitution in Pediatric Aplastic Anemia after Allogeneic Hematopoietic Stem-cell Transplantation.2022International journal of medical sciencesFree full text
  8. Efficacy of hematopoietic stem cell transplantation in the treatment of children with non-severe aplastic anemia.2022Pediatric transplantation
  9. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children.2021Pediatric hematology and oncology
Chinese-language papers (not in the count)3
  1. [Prognostic factors of immunosuppression therapy combined with eltrombopag in the treatment of childhood severe aplastic anemia].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Three cases of aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
  3. [Progress in pathogenesis of bone marrow failure in Fanconi anemia].2022Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 31 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 7.8%.

Papers led
31
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 9920222023: 7720232024: 7720242025: 442025

11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07488728

    Age Not stated to 18 years (registered criteria)

    Led by Beijing Children's HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChildrenTreatment regimensGenetics & inherited forms
Departments in papersPediatricsMedical oncology
Papers it led31
  1. Long-Term Outcomes of a Stratified Treatment Regimen Based on Etoposide and Glucocorticoids in Children With Hemophagocytic Lymphohistiocytosis (CCHG-HLH-2018): A Multicenter, Single-Arm Clinical Study.2026American journal of hematology
  2. Efficacy of emapalumab in treating 3 pediatric patients with epstein-barr virus-associated hemophagocytic lymphohistiocytosis complicated by multiple organ dysfunction.2025Annals of medicineFree full text
  3. Efficacy and safety of ruxolitinib-based regimen in the treatment of paediatric Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.2025British journal of haematology
  4. Hospitalization trends and clinical burden of paediatric haemophagocytic lymphohistiocytosis in a multicentre study in China.2025British journal of haematology
  5. Ruxolitinib-based regimen in children with autoimmune disease or autoinflammatory disease-related haemophagocytic lymphohistiocytosis.2025British journal of haematology
  6. Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH).2024Annals of hematology
  7. Genetic and clinical characteristics of primary hemophagocytic lymphohistiocytosis in children.2024Annals of hematology
  8. Ruxolitinib-based regimen in children with primary hemophagocytic lymphohistiocytosis.2024Haematologica
  9. Biomarkers in Pediatric Hemophagocytic Lymphohistiocytosis With Central Nervous System Involvement: A Cohort Study.2024Journal of pediatric hematology/oncology
  10. Ruxolitinib Monotherapy for a Child With HAVCR2 Gene Mutation Associated Subcutaneous Panniculitis-like T-cell Lymphoma: A Case Report.2024Journal of pediatric hematology/oncology
  11. Familial Hemophagocytic Lymphohistiocytosis Type 2 Presenting With Isolated Facial Palsy.2024Journal of pediatric hematology/oncology
  12. Three pediatric cases of Staphylococcus aureus-associated hemophagocytic lymphohistiocytosis.2024Pediatrics and neonatology
  13. Serum cytokine pattern in children with hemophagocytic lymphohistiocytosis.2023Annals of hematologyFree full text
  14. Efficacy of ruxolitinib for HAVCR2 mutation-associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children.2023British journal of haematology
  15. Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug-drug interactions.2023Cancer chemotherapy and pharmacology
  16. Subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic lymphohistiocytosis: a systematic review of 63 patients reported in the literature.2023Clinical and experimental medicine
  17. Clinical Significance of Plasma Soluble MICB in Children With EBV-associated Hemophagocytic Lymphohistiocytosis.2023Journal of pediatric hematology/oncology
  18. Epstein-Barr virus-positive diffuse large B-cell lymphoma onset as familial hemophagocytic lymphohistiocytosis in an infant.2023Pediatric blood & cancer
  19. Manifestations of B-cell expansion with NF-κB and T-cell anergy disease overlapping with hemophagocytic lymphohistiocytosis.2023Scandinavian journal of immunology
  20. Development and application of an LC-MS/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis.2022Analytical methods : advancing methods and applications
  21. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.2022Blood
  22. 18F-FDG PET/CT for Identifying the Potential Primary Diseases and Predicting Prognosis of Secondary Hemophagocytic Lymphohistiocytosis in Children.2022Contrast media & molecular imagingFree full text
  23. Significance of serum Th1/Th2 cytokine levels in underlying disease classification of childhood HLH.2022Cytokine
  24. NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis.2022Journal of hematology & oncologyFree full text
  25. A retrospective study of 18 children with subcutaneous panniculitis-like T-cell lymphoma: multidrug combination chemotherapy or immunomodulatory therapy?2022Orphanet journal of rare diseasesFree full text
  26. Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.2022Orphanet journal of rare diseasesFree full text
  27. Clinical significance of cerebrospinal fluid soluble CD25 in pediatric hemophagocytic lymphohistiocytosis with central nervous system involvement.2022Pediatric blood & cancer
  28. Familial hemophagocytic lymphohistiocytosis onset as central diabetes insipidus in a child.2022Pediatric blood & cancer
  29. Successful rescue of a lethal Griscelli syndrome type 2 presenting with neurological involvement and hemophagocytic lymphohistiocytosis: a case report.2021BMC pediatricsFree full text
  30. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.2021HaematologicaFree full text
  31. Hemophagocytic Lymphohistiocytosis Associated with Histiocytic Necrotizing Lymphadenitis: A Clinical Study of 13 Children and Literature Review.2021The Journal of pediatrics
Chinese-language papers (not in the count)8
  1. [L-DEP regimen salvage therapy for refractory primary hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection in 4 children].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Analysis of 9 cases of drug induced hypersensitivity syndrome related hemophagocytic lymphohistiocytosis].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  3. [Progress in the application of targeted monoclonal antibodies in children with hemophagocytic syndrome].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
  4. [Efficacy and safety of modified hemophagocytic lymphohistiocytosis 04 regimen in Beijing Children's Hospital].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
  5. [Clinical and molecular characteristics of Streptococcus pneumoniae-associated hemophagocytic lymphohistiocytosis in children].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
  6. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].2022Zhonghua yi xue za zhi
  7. [Association between genotype and clinical phenotype in children with primary hemophagocytic lymphohistiocytosis].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
  8. [Hemophagocytic lymphohistiocytosis: update on pathogenesis, diagnosis, and treatment].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status2
  1. Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic LymphohistiocytosisRecruitingNCT07488728Lead sponsorN/AStart 2025-10
  2. Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLECompletedNCT05001737Study sitePhase 3Start 2021-12
More papers found outside PubMed (not counted)2
  1. Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis2022TigerPrints (Clemson University)article
  2. PP329 [Infections » Other]: CLINICAL CHARATERISTICS OF STREPTOCOCCUS PNEUMONIAE-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN CHILDREN WITH MOLECULAR FETURES OF STREPTOCOCCUS PNEUMONIAE2022Pediatric Critical Care Medicineconference-abstract

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

10 hospitals in Beijing for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Studies of Exagamglogene Autotemcel - Age and Place.2024The New England journal of medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 32 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 11.8%.

Papers led
32
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 9920212022: 6620222023: 7720232024: 5520242025: 552025

15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
    Phase
    Phase 3
    Started
    2024-04
    Registry
    NCT07437404

    Age Not stated to 6 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  2. Recruiting
    A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
    Phase
    Phase 3
    Started
    2022-12
    Registry
    NCT05611801

    Age 1 year to 17 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan

  3. Recruiting
    Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
    Phase
    Phase 3
    Started
    2021-11
    Registry
    NCT05145127

    Age 1 year to 74 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology
Papers it led32
  1. Analysis of the current situation and influencing factors of home treatment for children with hemophilia in China.2025Annals of hematology
  2. The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study.2025Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  3. Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing.2025Journal of thrombosis and haemostasis : JTH
  4. The Chinese Haemophilia Individualized Prophylaxis (CHIPS): A cost-effective regimen for zero joint bleeding and long-term joint health in boys with Severe Haemophilia A (SHA) on factor replacement.2025Thrombosis research
  5. A comparison of My Precise Dose and WAPPS-Hemo as dosing tools for optimizing prophylaxis in children with hemophilia A treated with BAY 81-8973.2025Thrombosis research
  6. Surgical procedures and complications in placement of totally implantable venous access port in pediatric hemophilia patients: A retrospective analysis.2024Blood cells, molecules & diseases
  7. Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Moderate or Severe Hemophilia A in China.2024Clinical therapeutics
  8. Oral health status and oral habits of children and adolescents with hemophilia: a report from the children's hemophilia comprehensive care center of China.2024European journal of pediatrics
  9. The influence of dead space in blood sampling needle on FVIII level and pharmacokinetic profiles in children with hemophilia.2024Hematology (Amsterdam, Netherlands)
  10. A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS).2024Thrombosis research
  11. Successful treatment of Henoch-Schönlein purpura-associated hematochezia in a child with hemophilia A: a case report.2023BMC pediatrics
  12. Application of peripherally inserted central catheter in immune tolerance induction treatment of children with hemophilia A and accompanying inhibitors in China.2023Hematology (Amsterdam, Netherlands)
  13. Machine learning model for predicting physical activity related bleeding risk in Chinese boys with haemophilia A.2023Thrombosis research
  14. Early immune tolerance induction is a unique predictor of favorable outcomes in hemophilia A children with intron 22 inversion and high-responding inhibitors.2023Thrombosis research
  15. Low-dose immune tolerance induction therapy in severe hemophilia a children in China: Starting earlier resulted in better inhibitor eradication outcomes.2023Thrombosis research
  16. The efficacy of sequential MMF-rescue-regimen to eradicate inhibitors for refractory severe hemophilia A inhibitor children in China.2023Thrombosis research
  17. The efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China.2023Thrombosis research
  18. Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A.2022Haemophilia : the official journal of the World Federation of Hemophilia
  19. Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia.2022Haemophilia : the official journal of the World Federation of Hemophilia
  20. Altered brain activity and functional networks in school-age boys with severe haemophilia A: A resting-state functional magnetic resonance imaging study.2022Haemophilia : the official journal of the World Federation of Hemophilia
  21. Eradication of FIX inhibitor in haemophilia B children using low-dose immune tolerance induction with rituximab-based immunosuppressive agent(s) in China.2022Haemophilia : the official journal of the World Federation of Hemophilia
  22. "A personalized limited sampling approach to better estimate terminal half-life of FVIII concentrates": Comment from Huang et al.2022Journal of thrombosis and haemostasis : JTH
  23. Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A.2022Thrombosis research
  24. Pharmacokinetics and complementary evaluation system-based guidance on prophylaxis of paediatric patients with haemophilia A in China with Kovaltry: protocol of the LEAP study.2021BMJ open
  25. Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China.2021Clinical therapeutics
  26. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A.2021Haemophilia : the official journal of the World Federation of Hemophilia
  27. Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with severe hemophilia A.2021Haemophilia : the official journal of the World Federation of Hemophilia
  28. A low-dose immune tolerance induction (ITI) protocol incorporating immunosuppressive agents in haemophilia A children with high-titre factor VIII inhibitor and poor-ITI prognostic risk.2021Haemophilia : the official journal of the World Federation of Hemophilia
  29. Comparative pharmacokinetics of Kogenate FS and Kovaltry in 14 Chinese paediatric patients with haemophilia A: A single-centre study.2021Haemophilia : the official journal of the World Federation of Hemophilia
  30. Development and desensitization therapy of high-response factor VIII inhibitors with severe allergic reaction in a moderate hemophilia A patient.2021International journal of immunopathology and pharmacology
  31. Generation of induced pluripotent stem cell, BCHSCTi001-A, derived from a Hemophilia A patient with F8 (p. R391C) mutation.2021Stem cell research
  32. Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A.2021The Journal of biological chemistry
Chinese-language papers (not in the count)1
  1. [Clinical efficacy and safety of Octocog alfa in Chinese patients with hemophilia A: One-year follow-up results from the Antihemophilic Factor Hemophilia A Outcome Database (AHEAD) study].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Earlier papers (2016–2020)14
  1. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.2020Haemophilia : the official journal of the World Federation of Hemophilia
  2. A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations.2020International journal of immunopathology and pharmacology
  3. Bleeds and imaging scoring scales in relation to pharmacokinetics of coagulation factor VIII in Chinese pediatric patients with severe hemophilia A.2020Thrombosis research
  4. Hemophilia Gene Therapy: New Development from Bench to Bed Side.2019Current gene therapy
  5. Common themes and challenges in hemophilia care: a multinational perspective.2019Hematology (Amsterdam, Netherlands)
  6. Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.2018Chinese medical journal
  7. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.2018Haemophilia : the official journal of the World Federation of Hemophilia
  8. Describing the quality of life of boys with haemophilia in China: Results of a multicentre study using the CHO-KLAT.2018Haemophilia : the official journal of the World Federation of Hemophilia
  9. [Analysis of the arthropathies on no-bleeding history joints in pre-school age severe hemophilia A children].2018Zhonghua er ke za zhi = Chinese journal of pediatrics
  10. The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study.2017Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  11. The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China.2017Expert review of hematology
  12. A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment.2017Haemophilia : the official journal of the World Federation of Hemophilia
  13. Preliminary evaluation of altered brain microstructure in the emotion-cognition region in children with haemophilia A: a diffusional kurtosis imaging study.2017Haemophilia : the official journal of the World Federation of Hemophilia
  14. [Analysis of individualized primary prophylactic treatment of 19 cases of children with severe hemophilia A].2016Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status23
  1. Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in ChinaStatus unknownNCT03598725Lead sponsorPhase 4Start 2016-01
  2. A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A ChildrenStatus unknownNCT02999308Lead sponsorPhase 4Start 2016-08
  3. Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.RecruitingNCT07437404Study sitePhase 3Start 2024-04
  4. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Study sitePhase 3Start 2022-12
  5. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Study sitePhase 3Start 2021-11
  6. Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia ANot yet recruitingNCT06136507Study sitePhase 3Start 2026-12
  7. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedNCT06738485Study sitePhase 3Start 2025-01
  8. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Study sitePhase 3Start 2023-03
  9. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia AActive, not recruitingNCT05685238Study sitePhase 3Start 2023-02
  10. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without InhibitorsCompletedNCT05306418Study sitePhase 3Start 2022-04
  11. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)CompletedNCT05082116Study sitePhase 3Start 2021-09
  12. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  13. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsCompletedNCT05053139Study sitePhase 3Start 2021-12
  14. A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ,Fc Fusion Protein for InjectionCompletedNCT05251090Study sitePhase 1Start 2021-06
  15. Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BCompletedNCT03938792Study sitePhase 3Start 2020-03
  16. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  17. A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia ACompletedNCT04565236Study sitePhase 4Start 2020-09
  18. A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionStatus unknownNCT03747653Study siteStart 2019-03
  19. Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsCompletedNCT03315455Study sitePhase 3Start 2018-04
  20. Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia ACompletedNCT02461992Study sitePhase 1Start 2015-07
  21. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia ACompletedNCT02492984Study sitePhase 4Start 2015-04
  22. China ADVATE PTP StudyCompletedNCT02170402Study sitePhase 4Start 2014-06
  23. ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)CompletedNCT02078427Study siteStart 2011-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 2 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 7.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

6 hospitals in Beijing for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Analysis of five children with acquired thrombotic thrombocytopenic purpura].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
Earlier papers (2016–2020)1
  1. [Analysis of 5 children with congenital thrombotic thrombocytopenic purpura].2019Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status1
  1. A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraActive, not recruitingNCT04683003Study sitePhase 3Start 2021-04

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Beijing for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. A case of ADH5/ALDH2 deficiency combined with 3q29 microduplication syndrome.2025BMC pediatricsFree full text
Chinese-language papers (not in the count)1
  1. [Progress in pathogenesis of bone marrow failure in Fanconi anemia].2022Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosisPregnancy, children, older adultsOptic nerve & vision
Departments in papersOphthalmology / neuro-ophthalmologyNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

8 hospitals in Beijing for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & blood flowStroke & bleeding outcomesChildren
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 15 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 7.0%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 6620222023: 3320232024: 1120242025: 222025

3 hospitals in Beijing for biliary atresia28 hospitals in China for biliary atresia

No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesScreening & diagnosisDisease mechanismsKasai operation
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led15
  1. S1P/S1PR4 promotes the differentiation of CD8+ tissue-resident memory T cells aggravating bile duct injury in biliary atresia.2026Journal of hepatology
  2. SULT2B1 promotes cholangiocyte epithelial-mesenchymal transition via Wnt/β-catenin/MMP7 pathway in biliary atresia.2026Pediatric researchFree full text
  3. Is performing the Kasai portoenterostomy in the neonatal period associated with a better prognosis? A single-center, retrospective cohort study from China.2025BMC pediatricsFree full text
  4. Development and validation of a screening model for early diagnosis of biliary atresia in neonates with cholestasis.2025Pediatric surgery international
  5. Development of a diagnostic model for biliary atresia based on MMP7 and serological tests using machine learning.2024Pediatric surgery international
  6. Necroptosis of macrophage is a key pathological feature in biliary atresia via GDCA/S1PR2/ZBP1/p-MLKL axis.2023Cell death & diseaseFree full text
  7. Laparoscopic indocyanine green fluorescence imaging technique in rare type II cystic biliary atresia.2023Photodiagnosis and photodynamic therapy
  8. Preliminary exploration of the efficacy of laparoscopic fluorescence cholangiography (LFC) in the diagnosis of biliary atresia compared with intraoperative cholangiography (IOC).2023Photodiagnosis and photodynamic therapy
  9. Development and validation of a novel nomogram and risk score for biliary atresia in patients with cholestasis.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  10. The utility of shear wave elastography and serum biomarkers for diagnosing biliary atresia and predicting clinical outcomes.2022European journal of pediatrics
  11. Comprehensive Analysis of Gut Microbiota and Fecal Bile Acid Profiles in Children With Biliary Atresia.2022Frontiers in cellular and infection microbiologyFree full text
  12. Identifying and validating molecular subtypes of biliary atresia using multiple high-throughput data integration analysis.2022Frontiers in immunologyFree full text
  13. Diagnosis of liver cirrhosis with two-dimensional shear wave elastography in biliary atresia before Kasai portoenterostomy.2022Pediatric surgery international
  14. Exploratory application of indocyanine green quantification in biliary atresia observational study.2022Photodiagnosis and photodynamic therapy
  15. Development and Validation of a Nomogram Incorporating Ultrasonic and Elastic Findings for the Preoperative Diagnosis of Biliary Atresia.2021Academic radiology
More papers found outside PubMed (not counted)4
  1. A Transfer Learning-Based Diagnostic Model for Biliary Atresia: A Multicenter Study with 389 Cases2025Research Squarepreprint
  2. IDDF2024-ABS-0207 S1P/S1PR4 promotes the differentiation of CD8+TRM cells aggravating bile duct injury in biliary atresia2024Gutconference-paper
  3. IDDF2024-ABS-0285 Ferritinophagy activation and sideroflexin3-dependent mitochondrial iron overload contribute to biliary epithelial cells epithelial-mesenchymal transition and liver fibrosis in biliary atresia2024Gutconference-paper
  4. IDDF2024-ABS-0308 YQHX inhibits hepatic stellate cells activation by suppressing NCOA4-mediated ferritinophagy in biliary atresia2024Gutconference-paper

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 4 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 1120242025: 002025

13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led4
  1. Autoimmune Basal Ganglia Encephalitis Associated With Anti-N-methyl-d-Aspartate Receptor Antibodies in Children.2024Pediatric neurology
  2. Pediatric anti-N-methyl-D-aspartate receptor encephalitis with MOG-Ab co-existence: Relapse propensity and treatability.2022Multiple sclerosis and related disorders
  3. Age-dependent characteristics and prognostic factors of pediatric anti-N-methyl-d-aspartate receptor encephalitis in a Chinese single-center study.2021European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  4. Clinical Features and Outcomes of Anti-N-Methyl-d-Aspartate Receptor Encephalitis in Infants and Toddlers.2021Pediatric neurology
Chinese-language papers (not in the count)1
  1. [Risk factors and prognosis of anti-N-methyl-D-aspartate receptor encephalitis following herpes simplex virus encephalitis in children].2025Zhonghua er ke za zhi = Chinese journal of pediatrics
Earlier papers (2016–2020)2
  1. [Clinical observation on the overlapping syndrome of myelin oligodendrocyte glycoprotein antibody and anti-N-methyl-D aspartate receptor in children].2020Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Clinical and electroencephalographic analysis of anti-N-methyl-D-aspartate receptor encephalitis in children].2016Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisActive, not recruitingNCT05503264Study sitePhase 3Start 2022-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 3 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 0020242025: 002025

30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

19 hospitals in Beijing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

8 hospitals in Beijing for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06971094

    Age 2 years to 12 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Shenzhen, Suzhou, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Beijing for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Fabry Aim Children Early (ACE) ProjectWithdrawnNCT04965467Study siteStart 2021-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

11 hospitals in Beijing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

7 hospitals in Beijing for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyENT / head & neck surgery
Papers it led1
  1. Alport syndrome complicated with steroid-sensitive nephrotic syndrome: a case report.2025Pediatric nephrology (Berlin, Germany)
Chinese-language papers (not in the count)1
  1. [Long-term auditory monitoring in children with Alport syndrome based on different degrees of renal injury].2024Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 7 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.9%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 3320232024: 1120242025: 002025

32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyPathology / laboratory medicine
Papers it led7
  1. Predictive role of Oxford Classification for prognosis in children with IgA nephropathy: a systematic review and meta-analysis.2024Renal failure
  2. Long noncoding RNA FGD5-AS1 alleviates childhood IgA nephropathy by targeting PTEN-mediated JNK/c-Jun signaling pathway via miR-196b-5p.2023Experimental cell research
  3. Clinical relevance of glomerular C4d deposition in children with early IgA nephropathy or Henoch-Schönlein purpura nephropathy.2023Pediatric nephrology (Berlin, Germany)
  4. Characteristics of children with IgA nephropathy.2023Pediatric research
  5. Contrast-enhanced ultrasonography for assessing histopathology in pediatric immunoglobulin A nephropathy and Henoch-Schönlein purpura nephritis.2022Pediatric radiology
  6. Mesangial C3 deposition and serum C3 levels predict renal outcome in IgA nephropathy.2021Clinical and experimental nephrology
  7. Serum levels of galactose-deficient IgA1 in Chinese children with IgA nephropathy, IgA vasculitis with nephritis, and IgA vasculitis.2021Clinical and experimental nephrology
Chinese-language papers (not in the count)1
  1. [Hemolytic uremic syndrome complicated with IgA nephropathy: a clinicopathological study].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
Earlier papers (2016–2020)5
  1. MicroRNA‑196b targets COSMC in pediatric IgA nephropathy.2020Molecular medicine reports
  2. The Characteristics of Intestinal-Barrier Damage in Rats With IgA Nephropathy.2020The American journal of the medical sciences
  3. A clinicopathological comparison between IgA nephropathy and Henoch-Schönlein purpura nephritis in children: use of the Oxford classification.2019Clinical and experimental nephrology
  4. [Role of IgG antibody to galactose-deficient IgA1 in children with IgA nephropathy].2017Zhonghua er ke za zhi = Chinese journal of pediatrics
  5. Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.2016PloS one

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Beijing for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 13 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 8.1%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 4420222023: 1120232024: 2220242025: 332025

8 hospitals in Beijing for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led13
  1. Total Transanal Endorectal Pull-through Versus Laparoscopic-Assisted Approach in Children with Rectosigmoid Hirschsprung's Disease: A Systematic Review and Meta-Analysis.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  2. Risk factors for Hirschsprung's disease in infancy: A study from the NHANES database.2025Medicine
  3. Risk factors of bowel perforation in neonates with Hirschsprung disease.2025Pediatric surgery international
  4. Surgical outcomes for patients with rectosigmoid hirschsprung disease who underwent transanal endorectal pull-through after 1 year of age.2024BMC surgery
  5. Bowel perforation in neonates with Hirschsprung disease: a case series and literature review.2024Pediatric surgery international
  6. Long-term bowel function after single-stage transanal endorectal pull-through in neonatal patients with Hirschsprung disease.2023Pediatric surgery international
  7. Risk factors for Hirschsprung-associated enterocolitis following Soave: a retrospective study over a decade.2022BMC pediatrics
  8. Risk factors of enterostomy in neonates with Hirschsprung disease.2022International journal of colorectal disease
  9. Three dimension high-definition manometry in evaluation of anorectal function in 104 normal infants and children: A clinical study from China.2022Neurogastroenterology and motility
  10. One-stage transanal endorectal pull-through for Hirschsprung disease: experience with 229 neonates.2022Pediatric surgery international
  11. Redo Transanal Soave Pull Through with or without Assistance in Hirschsprung Disease: An Experience in 46 Patients.2021European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie
  12. Rectourethral and rectovesical fistula as serious and rare complications after Hirschsprung disease operation: Experience in seven patients.2021Journal of pediatric surgery
  13. Vascular Malformation of the Colorectum in Children: Case Series of 27 Patients.2021World journal of surgery
Earlier papers (2016–2020)3
  1. Barium enema findings in total colonic aganglionosis: a single-center, retrospective study.2020BMC pediatrics
  2. Clinical Outcomes After Staged and Primary Laparotomy Soave Procedure for Total Colonic Aganglionosis: a Single-Center Experience from 2007 to 2017.2020Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  3. STROBE-anastomotic leakage after pull-through procedure for Hirschsprung disease.2018Medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Beijing for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Majeed syndrome

Majeed 综合征

Led no English-language PubMed papers on Majeed syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Beijing for Majeed syndrome7 hospitals in China for Majeed syndrome

No open trial on Majeed syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

首都医科大学附属北京儿童医院

Beijing Children's Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Beijing Children Hospital; Beijing Children's Hospital Affiliated to Capital Medical University; Beijing Children's Hospital Affiliated With Capital Medical University; BeiJing Children's Hospital; Ministry of Education Beijing Children's Hospital; Xinjiang Hospital of Beijing Children's Hospital; Affiliated Beijing Children's Hospital; Beijing Children’s Hospital

Suggest a correctionDownload the data